| Print
United Therapeutics Corp (UTHR)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Address
1040 Spring Street
Silver Spring
MD
USA
20910
Telephone
+1 202 9194097
Forecast key dates
| Name | Key Date |
|---|---|
| United Therapeutics Corp Third Quarter Earnings Conference Call for 2026 | 2026-10-29T09:00:00 |
| United Therapeutics Corp Third Quarter Earnings Results for 2026 | 2026-10-29T00:00:00 |
| United Therapeutics Corp Second Quarter Earnings Conference Call for 2026 | 2026-07-30T09:00:00 |
| United Therapeutics Corp Second Quarter Earnings Results for 2026 | 2026-07-30T06:30:00 |
| United Therapeutics Corp Annual General Meeting for 2026 | 2026-06-26T10:30:00 |
| United Therapeutics Corp First Quarter Earnings Conference Call for 2026 | 2026-04-30T09:00:00 |
| United Therapeutics Corp First Quarter Earnings Results for 2026 | 2026-04-30T06:30:00 |
| United Therapeutics Corp Fourth Quarter Earnings Conference Call for 2025 | 2026-02-26T09:00:00 |
| United Therapeutics Corp Fourth Quarter Earnings Results for 2025 | 2026-02-26T06:30:00 |
| United Therapeutics Corp Annual Report for 2025 | 2026-02-26T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.